SEI Healthcare Launches New AATD Educational Program and Interactive Webinar

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

SEI Healthcare recently announced the successful launch of an educational program and interactive webinar on Alpha-1 Antitrypsin Deficiency (AATD)

Lewes, Delaware–(Newsfile Corp. – July 22, 2022) – SEI Healthcare, a global, professional independent medical education organization, announced the successful launch of an educational program and interactive webinar on alpha deficiency -1 antitrypsin (AATD), titled “Paradigm shifts in AATD and impact on patient management”. This program included the development of four patient case simulations on a live interactive webinar, which was attended by over 1900 healthcare professionals (HCPs). The full program, including the on-demand webinar, will remain available as enduring content on HowITreat.MD.

Paradigm shifts in AATD and impact on patient management

To view an enhanced version of this graphic, please visit:

This educational program was developed with the help of:

Professor Felix Herth (Department of Pulmonology and Intensive Care Medicine, University of Heidelberg, Germany)

Professor Daiana Stolz (Pneumology Department, Medical Center of the University of Freiburg, Germany).

Professor Dave Singh (Division of Immunology, Infection Immunity and Respiratory Medicine, University of Manchester, UK).

Supported by CSL Behring, this HowITreat.MD educational program focuses on the early diagnosis and management of AATD in different patient groups, within the context of the best available evidence and current clinical practice guidelines.

This program aims to educate healthcare professionals on how to approach a variety of clinical scenarios within the AATD, covering a number of key topics, such as:

  • Etiology of lung and liver diseases associated with AATD

  • Role of genetic and environmental factors in AATD

  • Unmet medical needs of patients with AATD. AATD Screening Clinical Presentations of Patients with AATD

  • Diagnostic approach in patients suspected of AATD

  • AATD genotypes and their impact on diagnosis and management

  • Treatments currently available for the management of AATD

Professor Felix Herth says: “AATD is a rare and often forgotten disease. All guidelines recommend testing all patients with COPD, but in reality this does not happen and patients do not receive augmentation treatment for years. This program aims to help healthcare professionals understand who to test and how to identify patients for testing, recognize the importance of early diagnosis and treatment of AATD, and describe the disease and any processing issues.

Professor Daiana Stolz says: “This is a highly appreciated compact and informative webinar focusing on what doctors need to know about alpha-1-antypsin deficiency – the most common inherited disorder in adults. case-based format highlights important insights and answers common questions around clinical presentation, screening, and augmentation therapy. Worth a look!”

Professor Dave Singh says: “Alpha 1-antitrypsin deficiency is an underrecognized cause of COPD, and perhaps some clinicians are unsure of the optimal clinical management. This project highlights common clinical cases, showing valuable concepts that I’m sure will help improve management.”

“It was a pleasure to work with Professors Herth, Stolz and Singh on this project. They are clearly experts in their field and have great pooled knowledge about AATD which resulted in the creation of “An exceptionally high-quality educational program covering a wide range of clinical scenarios, from pediatric patients to elderly patients,” said Dr. Rita Aresta, Chief Medical Officer at SEI Healthcare.

More details about this educational program can be found at:

“An educational project on this subject has proven to be extremely important. SEI Healthcare is pleased to continue to develop educational projects providing strategic insights to optimize outcomes,” said Leana Ribeiro, Global Account Manager for SEI Healthcare.

About SEI Health

Founded in 2007, SEI Healthcare is a global professional organization specializing in independent medical education. With a dedicated commitment to bringing medical education to the forefront of innovation globally.

SEI Healthcare: visit

For educational solutions, visit: and

Contact information:

Name: Samantha Harrison
E-mail: [email protected]
Organization: SEI Health
Address: Mailing Address 16192 Coastal Highway Lewes, Lewes, Delaware 19958, USA

To view the source version of this press release, please visit

Back To Top